In Vivo Fluorescent Imaging Using Cyclic-Arginine -Glycine-Aspartic Acid Peptide And Peg Modified Europium Nanoparticle
we report a novel strategy to prepare Eu3+ nanoprobes for in vivo HepG-2 tumor-bearing mice imaging by conjugation of cyclic-arginine-glycine-aspartic acid peptide (cyclic-RGD) for tumor specific recognition, and PEG to improve biocompatibility and increase the circulation time. These Eu3+ nanoprobes exhibit excellent luminescent properties, high dispersion stability in water solutions and no cytotoxicity in living tumor cells after 24 h incubation. The Eu3+ nanoprobes can be completely cleared after 13 days from liver to feces and not be sequestered in blood and tissues which ensure the security of the nanoprobes for in vivo applications. The results report here provides a new perspective for the Eu3+ nanoprobes in biomedical applications.
Index Terms- Nanoparticles; In vivo imaging; tumor specificity; Excretion pathway; Nontoxicity.